908 Devices Inc. ( (MASS) ) has released its Q2 earnings. Here is a breakdown of the information 908 Devices Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
908 Devices Inc. is a small-cap growth company specializing in handheld chemical analysis tools for health, safety, and defense applications. The company recently released its second-quarter 2025 financial results, showcasing a 14% increase in revenue from continuing operations compared to the previous year. This growth was driven by strong sales of handheld products and services, alongside strategic initiatives to enhance profitability.
Key financial highlights include a total revenue of $13.0 million for the quarter, with recurring revenue rising by 28% year-over-year to represent 36% of total revenues. The company achieved a record number of XplorIR device placements and successfully launched the VipIR, a new handheld chemical analyzer. Additionally, 908 Devices completed a manufacturing consolidation to improve cost efficiency and acquired assets from KAF Manufacturing to secure its supply chain.
Despite these achievements, the company reported a net loss from continuing operations of $12.9 million, an increase from the $7.6 million loss in the same period last year. The adjusted EBITDA also reflected a loss of $3.9 million. Operating expenses rose due to non-cash charges and restructuring costs, although the company maintains a strong cash position with $118.6 million in cash, cash equivalents, and marketable securities.
Looking forward, 908 Devices has raised its revenue outlook for 2025, expecting growth between 13% and 17% compared to 2024. The management remains optimistic about the company’s long-term growth prospects, supported by an improving funding landscape and increasing demand for its innovative handheld solutions.